Composition for transdermal delivery of glutathione

ABSTRACT

A transdermal formulation which can be applied to the skin as a latex-free hypoallergenic adhesive patch or transdermal delivery cream using a combination of glutathione, Vitamin D, glycol, sodium bicarbonate and base cream resilient in the presence of a wide range of drugs while increasing permeation of active antioxidant agents, water, isopropyl myristate, polyoxyethylene sorbitan monooleate, isopropyl palmitate, ascorbic acid, and dimethyl sulfoxide. The dosage amount can create in the patient (i) regulation of sleep, (ii) increased energy during awake periods, (iii) improved concentration during awake periods, (iv) reduction of facial wrinkles, and (v) reduction of joint and muscular pain with increases by at least 10 percent of the ability of skin to retain moisture and totally absorb the glutathione without requiring injection or oral supplementation of the glutathione.

CROSS REFERENCE TO RELATED APPLICATIONS

The present application claims priority to and the benefit of co-pendingU.S. Provisional Patent Application Ser. No. 62/341,562 filed on May 25,2016, entitled “COMPOSITION FOR TRANSDERMAL DELIVERY OF GLUTATHIONATE”.This reference is hereby incorporated in its entirety.

FIELD

The present embodiments generally relate to a composition fortransdermal delivery of glutathione.

BACKGROUND

A need exists for a transdermal delivery system for glutathione toreduce nausea in patients.

The present embodiments meet these needs.

BRIEF DESCRIPTION OF THE FIGURE

The detailed description will be better understood in conjunction withthe accompanying drawings as follows:

FIG. 1 depicts a transdermal delivery system according to one or moreembodiments.

FIG. 2 depicts a detail of the latex-free hypoallergenic adhesive patchaccording to one or more embodiments.

FIG. 3 depicts Formulation 4 according to one or more embodiments.

FIG. 4 depicts Formulation 5 according to one or more embodiments.

FIG. 5 depicts Formulation 6 according to one or more embodiments.

FIG. 6 depicts Formulation 7 according to one or more embodiments.

FIG. 7 depict Formulation 8 according to one or more embodiments.

FIG. 8 depicts Formulation 9 according to one or more embodiments.

FIG. 9 depicts Formulation 10 according to one or more embodiments.

FIG. 10 depicts Formulation 11 according to one or more embodiments.

FIG. 11 depicts Formulation 12 according to one or more embodiments.

FIG. 12 depicts Formulation 13 according to one or more embodiments.

FIG. 13 depicts Formulation 14 according to one or more embodiments.

FIG. 14 depicts Formulation 15 according to one or more embodiments.

FIG. 15 depicts Formulation 16 according to one or more embodiments.

FIG. 16 depicts Formulation 17 according to one or more embodiments.

The present embodiments are detailed below with reference to the listedFigures,

DETAILED DESCRIPTION OF THE EMBODIMENTS

Before explaining the present apparatus in detail, it is to beunderstood that the apparatus is not limited to the particularembodiments and that it can be practiced or carried out in various ways.

The present embodiments generally relate to a composition fortransdermal delivery of glutathione.

The present embodiment further relate to a transdermal formulation whichcan be applied as a latex-free hypoallergenic adhesive patch ortransdermal delivery cream using a combination of glutathione, VitaminD, arnica, glycol, a buffer and a base cream resilient in the presenceof a wide range of drugs while increasing permeation of activeantioxidant agents, water, isopropyl myristate, polyoxyethylene sorbitanmonooleate, isopropyl palmitate, ascorbic acid, and dimethyl sulfoxide.

In embodiments, the buffer can be sodium bicarbonate with a pH from 5-8.

For patients unable to take antioxidants and vitamins in more commonforms, such as pills and injections, the use of a transdermalformulation can often mean the difference between treatment success ortreatment failure.

in embodiments, transdermal formulation can be administered as atransdermal delivery cream or in the form of a latex-free hypoallergenicadhesive patch allowing antioxidants and vitamins to successfullypenetrate the skin.

Also, vitamin D can improve absorption of glutathione.

In embodiments, the transdermal formulation can avoid many common sideeffects of drugs, such as upset stomach, and minimize the effects onother organs.

For example, the reduction of side effects is particularly significantin sleep treatment, where the application of the formulation can belocalized to an area with relatively low blood-flow. Therefore, higherconcentrations at the site of application and lower concentrations ofthe drug throughout the body enable a patient to restfully stay asleep.

A benefit of the embodiments is that the transdermal formulation canhelp prevent an early onset of aging and cancer in patients, which cancause an accelerated death. The embodiments can help save lives byproviding preventive care to patients to avoid life threatening illness.

The transdermal formulation can be a hypoallergenic delivery system. Inembodiments, the transdermal formulation can use a delivery system thatis latex-free. Latex is a toxic material, which can be harmful to theenvironment and cause some individuals to have a significant allergicreaction, such as irritating itchy rashes and even anaphylactic shock.

The embodiments can provide an easy to apply latex-free hypoallergenicadhesive patch that does not require special nursing skills or childproof containers. The package can be easily opened from a vacuum sealedsleeve.

The embodiments can provide a drug delivery system, which can preventindividuals from choking on the medication.

In embodiments, the invention can be a transdermal formulation in acarrier, such as a cream, a gel or a foam, For example, the transdermalformulation as a cream can be 0.1 weight percent to 5 weight percentglutathione and 0.1 weight percent to 5 weight percent aloe. An exampleof the transdermal formulation of a gel can be 0.1 weight percent to 5weight percent glutathione, 0.5 weight percent to 5 weight percent aloe,and 0.5 weight percent to 5 weight percent arnica. An example of thetransdermal formulation as a foam can be 0.1 weight percent to 5 weightpercent glutathione, 0.5 weight percent to 5 weight percent Vitamin D,and 0.5 weight percent to 3 weight percent aloe.

In embodiments, the glutathione can be a powder.

In embodiments, the latex-free hypoallergenic adhesive patch can have afirst side and a second side. In embodiments, the latex-freehypoallergenic adhesive patch can be from 1 centimeter×1 centimeter to 3centimeters×3 centimeters. In embodiments, the transdermal formulationand a magnesium component can be disposed on the same side of thelatex-free hypoallergenic adhesive patch.

In embodiments, the type of adhesive used for the latex-freehypoallergenic adhesive patch can be an acrylic adhesive.

The latex-free hypoallergenic adhesive patch can be formed from acontinuous sheet of a type of dosed cell foam, known as polyethylenefoam, which can be very thin such as from 0.001 millimeters to 0.2millimeters in thickness.

In embodiments, a layer of adhesive can be disposed on the closed foamin a thickness from 0.001 millimeters to 0.01 millimeters. The adhesivecan be an easily removable adhesive that does not cause rashes orotherwise aggravate the patient's skin. Also, the adhesive can bewaterproof.

In embodiments, the latex-free hypoallergenic adhesive patch can be areservoir patch with an absorbent pad and foam on the back or amonolithic patch.

In embodiments, a therapeutically effective amount of the transdermalformulation can be three different formulations.

Formulation 1:

In embodiments, the first formulation can have 4 weight percent to 10weight percent glutathione, 0.5 weight percent to 3 weight percentVitamin D, with no less than 1 unit and no more than 5000 units, 18weight percent to 20 weight percent glycol, 3 weight percent to 9 weightpercent sodium bicarbonate and 47 weight percent to 58 weight percentbase cream that is resilient in the presence of a wide range of drugswhile increasing permeation of active antioxidant agents.

In embodiments, a strip of magnesium glycinate can be attached on thefirst formulation. In embodiments, the strip of magnesium glycinate canbe one continuous strip that extends across the entire formulation. Inembodiments, the magnesium glycinate can be installed on the formulationas a series of strips, which can be offset from each other. The strip ofthe magnesium glycinate can be from ¼ centimeters to 10 centimeters inlength, from 0.25 centimeters to 15 centimeters in width and can coverfrom 1 percent to 100 percent of the latex-free hypoallergenic adhesivepatch.

In embodiments, the 1 weight percent to 20 weight percent magnesiumglycinate can be added to the transdermal delivery cream and alatex-free hypoallergenic adhesive patch.

The embodiments can provide a dosage amount of the formulation either ina transdermal delivery cream or on the latex-free hypoallergenicadhesive patch for delivery to a patient over a unit of time, such asfrom at least 24 hours to 48 hours.

The dosage amount creates in the patient (i) regulation of sleep, (ii)increased energy during awake periods, (iii) improved concentrationduring awake periods, (iv) reduction of facial wrinkles, and (v)reduction of joint and muscular pain, which can increase by at least 10percent the ability of skin to retain moisture and totally absorb theglutathione without requiring an injection or oral supplementation ofthe glutathione.

The following example depicts the therapeutic effects of the inventionusing formulation 1.

Formulation 1—Example 1

Bill, a 45 year old male, weighing 220 pounds and having Type 1 diabetesfasted from Midnight to 8:00 am prior to application of the transdermaldelivery system. Under a strong light at approximately 8:00 am, abaseline of wrinkles was visually computed as 2.2 wrinkles per side ofhis face for a total of 44 wrinkles.

The transdermal delivery system with formulation 1 can use the followingweight percents: 10 weight percent glutathione, 2 weight percent VitaminD (1000 units), 19 weight percent glycol, 3.5 weight percent sodiumbicarbonate, and 55.5 weight percent base cream was used.

In embodiments, formulation 1 can include 1 weight percent to 5 weightpercent arnica.

Formulation 1 on the latex-free hypoallergenic adhesive patch wasapplied to Bill's right forearm between the wrist and elbow for 46hours.

After 46 hours, the latex-free hypoallergenic adhesive patch was removedat approximately 11:00 am and the wrinkle count was found to be reducedto about 10 percent, which is a total 39 wrinkles +/−5 percent.

Formulation 1—Example 2

Mary, a 50 year old woman, weighing 135 pounds and having a significantamount of early onset wrinkles due to an immense amount of personalstress and too much sun exposure over an extensive period of time. Maryfasted from 10:00 pin until 6:00 am before the application oftransdermal delivery cream to her face. Under a strong light at 6:00 ama base line of deep wrinkles around the upper cheeks and crows linesbetween the eyebrows was visually computed as 15 deep wrinkles per sideof her upper face near eyes and between eyebrows for a total of 30wrinkles.

The transdermal delivery cream of formulation 1 can use the followingweight percent: 5 weight percent glutathione, 2 weight percent Vitamin D(1000 units), 18 weight percent glycol, 3.5 weight percent sodiumbicarbonate, and 46.5 weight percent base cream was used.

In embodiments, formulation 1 can include 1 weight percent to 5 weightpercent arnica and aloe.

After washing her face each time, the transdermal delivery cream wasapplied at 6:00 am each morning and 10:00 pm each evening.

The transdermal delivery cream application was halted after 48 hours atapproximately 10:00 pm. On the following morning at 6:30 am, the wrinklecount was found to have been reduced by 7 percent around the between theeyebrow and upper cheeks to a total of 9 wrinkles on each side andreduction of depths of the wrinkles by 5 percent.

Formulation 1—Example 3

Fred, a 75 year old man weighing 175 pounds, has a significant amount ofscrofulous eczema on the upper part of his face, ears and hairline. Fredhas a history of excessive drinking and smoking for at least 30 years.Fred has suffered persistent flaking and itching from the eczema formany years, Fred fasted from 11:00 pm until 7:00 am the followingmorning, with only an intake of 1 glass of water in the middle of thenight prior to the transdermal delivery system. Under a strong light, itwas noted that there were red patches, which had raised bumps on theupper cheeks below the eyes, red flaking patches along both sides of thehairline and redness on upper parts of his ears.

The latex-free hypoallergenic adhesive patch of formulation 1 can usethe following weight percents: 10 weight percent glutathione, 3 weightpercent Vitamin D (2000 units), 20 weight percent glycol, 15 weightpercent sodium bicarbonate, and 61.5 weight percent base cream was used.

In embodiments, formulation 1 can include 1 weight percent to 5 weightpercent arnica.

The latex-free hypoallergenic adhesive patch was applied at 7:15 am tothe under part of his upper left arm.

The latex-free hypoallergenic adhesive patch was removed after 48 hoursat approximately 7:00 am and the reduction of redness subsided by 30percent. The scrofulous flaking was reduced by 17 percent especially inthe highly affected areas along the hairline and the upper cheeks. Theitching was reduced by 20 percent giving significant relief during the48 hours of wearing the transdermal delivery system.

It should be noted that formulation 1 does not only affect wrinkles, butcan reduce the time of healing for burns and prevent oxidative stress.Oxidative stress is an imbalance between the production of free radicalsand the ability of the body to counteract or detoxify their harmfuleffects through neutralization by antioxidants.

Additionally, it should be noted that formulation I can assist in eczematreatment.

In embodiments, formulation 1 can be used for skin lightening.

Formulation 2

In embodiments, the second formulation can have 4 weight percent to 10weight percent glutathione, 75 weight percent to 85 weight percentwater, 3 weight percent to 9 weight percent sodium bicarbonate, and 0.1weight percent to 1 weight percent propylene glycol.

In embodiments, formulation 2 can include 1 weight percent to 5 weightpercent arnica.

Formulation 2—Example 1

Sally is a 60 year old woman who has had difficulty falling sleeping fortwo years since the death of her husband. Consistently, Sally cannotfall asleep before 12:00 am even though she retires at 10:00 pm. Inturn, Sally's energy dips at 2:00 pm each afternoon, approximately twohours after she eats lunch.

The latex-free hypoallergenic adhesive patch of formulation 2 can usethe following weight percents: 10 weight percent glutathione, 83 weightpercent water, 3.5 weight percent sodium bicarbonate, and 1.5 weightpercent propylene glycol.

In embodiments, formulation 2 can include 1 weight percent to 5 weightpercent arnica.

The latex-free hypoallergenic adhesive patch was administered at 6:30am, and she wore the latex-free hypoallergenic adhesive patch for 45hours. Sally reported that her energy at 2:00 pm increased by 12 percentthe first day and about 20 percent on the second day. Her sleep improvedsignificantly, and she was able to fall asleep one-half hour afterretiring to bed at 10:00 pm. Therefore, Sally had a significantimprovement of 90 percent,

Formulation 2—Example 2

Jessica is a 25 year old woman who wakes up consistently at 5:00 am andis unable to fall back asleep. Her energy dips at 4:00 pm during theday, but she gets another burst of energy at 9:00 pm preventing her fromgetting the requisite amount of sleep.

The transdermal delivery cream of formulation 2 can use the followingweight percents: 9 weight percent glutathione, 84.5 weight percentwater, 3.5 weight percent sodium bicarbonate, and 1.5 weight percentpropylene glycol.

In embodiments, formulation 2 can include 1 weight percent to 5 weightpercent arnica.

The transdermal delivery cream was administered at 9:00 pm and again at7:30 am for 48 hours on the temples of her face as well on her chest.Jessica reported that she did wake at 5:00 am both mornings hut was ableto fall back asleep fairly quickly and woke at 6:30 am feeling morerefreshed. Her energy at 4:00 pm was increased by 30 percent both daysand her 9:00 pm burst of energy subsided by 40 percent allowing her tofall asleep at 10:30 pm. Therefore, providing Jessica with almost asolid eight hours of sleep for 48 hours.

Formulation 2—Example 3

Malcolm is a 45 year old man who has celiac disease. He falls asleepalmost instantly when he lies down at 10:00 pm. He consistently wakes at2:00 am and can only fall back asleep at 4:30 am. He needs to wake up at6:00 am for work. His energy dips consistently each day between 3:00 pmand 6:00 pm.

The latex-free hypoallergenic adhesive patch of formulation 2 can usethe following weight percents: 10 weight percent glutathione, 84.5weight percent water, 4 weight percent sodium bicarbonate, and 1.5weight percent propylene glycol.

The latex-free hypoallergenic adhesive patch was administered at 9:30am, and he wore the latex-free hypoallergenic adhesive patch for 48hours. Malcolm reported that he woke up once the first night at 2:00 am,but fell back asleep almost immediately and slept through the nightcompletely the second night.

Malcolm also reported that his energy was 50 percent better throughoutboth days of wearing the latex-free hypoallergenic adhesive patch.

In embodiments, formulation 2 can additionally provide quantitativebenefits for the regulation of sleep and increased energy during awakeperiods.

In embodiments, formulation 2 can prevent leaky-gut syndrome, which canbe a result of celiac disease.

Formulation 3

In embodiments, the third formulation can have 4 weight percent to 10weight percent glutathione, 47 weight percent to 56 weight percentwater, 3 weight percent to 9 weight percent sodium bicarbonate 1, weightpercent to 5 weight percent polyoxyethylene sorbitan monooleate, 2weight percent to 5 weight percent ascorbic acid, and 4 weight percentto 10 weight percent dimethyl sulfoxide.

In embodiments, formulation 3 can include 1 weight percent to 5 weightpercent arnica.

In embodiments, formulation 3 can provide improved concentration duringawake periods and reduction of joint and muscular pain and increase theability of skin to retain moisture and totally absorb the glutathionewithout requiring injections or oral supplementation by at least 10percent while the formulation is on the skin either as a transdermaldelivery cream or a latex-free hypoallergenic adhesive patch.

In embodiments, the effects of the third formulation can continue for atleast 24 hours while the skin is still absorbing the formulation andcontinues to affect the body for at least 3 days and up to 6 daysdepending upon the age of the individual.

Formulation 3—Example 1

John is 72 years old and weighs 185 pounds and has terrible joint painsin his knees and legs. He also tends to bruise quite easily. John hasdifficulty climbing stairs and walking for long periods of time. Theright knee is worse than the left knee. His bruises are a deephemorrhagic purple presentation.

The latex-free hypoallergenic adhesive patch of formulation 3 can usethe following weight percents: 6 weight percent glutathione 3.5 weightpercent sodium bicarbonate, 56.5 weight percent water, 3 weight percentpolyoyethylene sorbitan monooleate, 3 weight percent ascorbic acid, 6weight percent dimethyl sulfoxide, and 3 weight percent arnica.

The latex-free hypoallergenic adhesive patch was applied to John's leftupper arm for 46 hours.

The latex-free hypoallergenic adhesive patch was removed after 46 hoursat approximately 6:00 am. John reported that his bruising had subsidedby 50 percent in presentation, and he felt a 30 percent improvementspecifically to the right knee and leg. John felt that it was easier toclimb stairs. Overall, there was a general reduction in pain.

Formulation 3—Example 2

David is 29 years of age, an athlete, and trains five days per week. Heoften will feel sore and is bruised. David has been experiencingdifficulty after training since his leg tendon injury two months before.The soreness is from the lower torso down. The pulled tendon is on theleft leg.

The transdermal delivery cream of formulation 3 can use the followingweight percents: 5 weight percent glutathione, 3.5 weight percent sodiumbicarbonate, 56.5 weight percent water, 2 weight percent polyoyethylenesorbitan monooleate, 2 weight percent ascorbic acid, 4 weight percentdimethyl sulfoxide, 5 weight percent arnica, and 3 weight percent aloe.

The transdermal delivery cream was applied to David's affected legs andupper shoulders for a total of 48 hours, He applied the transdermaldelivery cream after training at 11:00 am each day and before going tobed each night at 11:00 pm.

Within 20 minutes of the applying the transdermal delivery cream. Davidreported that there was immediate relief by 50 percent on the left legspecifically and an overall general reduction in stiffness and tearingpain. He noted that the pain had reduced before going into training onthe second day. David's overall pain, tightness and stiffnesssignificantly reduced to 75 percent on the second day after applying thetransdermal delivery cream.

Formulation 3—Example 3

Michael is 38 years of age and is a construction worker. He haspersistent bruising along his wrist and elbow pain on both sides.

The latex-free hypoallergenic adhesive patch of formulation 3 can usethe following weight percents: 10 weight percent glutathione, 15 weightpercent sodium bicarbonate, 61.5 weight percent water, 5 weight percentpolyoyethylene sorbitan monooleate, 5 weight percent ascorbic acid, 5weight percent dimethyl sulfoxide, and 4 weight percent arnica.

The latex-free hypoallergenic adhesive patch was applied to Michael at10:00 pm for 48 hours.

The latex-free hypoallergenic adhesive patch was removed 48 hours later.Michael. reported that the first night on retiring to sleep, hisstiffness and overall soreness was 50 percent better and turning andmoving in bed was easier. He woke up refreshed and his wrists were 30percent better and the bruising on the arms had subsided in color by 25percent. The second night, Michael did not feel stiffness or pain at allwhile sleeping. When he woke up, he noticed that his wrists were betterby 70 percent. He experienced easier flexibility and range of motion. Henoted that his bruising had subsided by 60 percent.

Turning now to the Figures, FIG. 1 depicts a transdermal delivery systemaccording to one or more embodiments.

The transdermal delivery system 10 can be applied to a user 11. Whilethe transdermal delivery system 10 is shown attached to the user'sforearm, it is understood that the transdermal delivery system can beattached to other areas of the user's body.

In embodiments, the transdermal delivery system 10 can be in the form ofa latex-free hypoallergenic adhesive patch 12, which can have a layer ofthe formulation 14, such as in the center of the latex-freehypoallergenic adhesive patch 12.

FIG. 2 depicts a detail of the latex-free hypoallergenic adhesive patchaccording to one or more embodiments.

The latex-free hypoallergenic adhesive patch 12 can have a backing layer19, which can be a thin film polymer that can be waterproof andhypoallergenic.

In embodiments, portions of an adhesive 16 a and 16 b can be positionedon the backing layer 19, such as on opposing edges but on the same sideas the layer of the formulation 14.

In embodiments, a plurality of offset strips of magnesium glycinate 20a, 20 b, and 20 c can be disposed on the layer of the formulation 14.

Formulation 4

FIG. 3 depicts Formulation 4.

When Formulation 4 is placed upon an arm, transdermal Formulation 4greatly increases the mental focus in both men and women of all ageswithin a time span of one hour. It will continue to help achieve clarityand focus for up to 48 hours at a time.

Formulation 5

FIG. 4 depicts Formulation 5. Formulation 5 can be applied as atransdermal cream or a gel to the skin for anti-aging as it activelystarts to repair the elasticity to the face by 10 percent in the first24 hours followed by a 10 percent reduction each day following with thereduction of wrinkles around the eyes.

Formulation 6

FIG. 5 depicts Formulation 6. Formulation 6 applied a cream is excellentfor bruising, muscle pain and acute injuries. Formulation 6 will reduceinflammation within 20 minutes of the application and pain will reducewithin 20 minutes of application leading to a 60 percent reduction indiscoloration of the bruise within 24 hours.

Formulation 7

FIG. 6 depicts Formulation 7. Formulation 7 applied as a cream or a gelaids in constipation and the reversal of issues pertaining to the gut;such as difficulty with stool, hemorrhoids and acid-reflux. Rectalbleeding should reverse itself within 24-48 hours. Acid-reflux willreduce within two hours of the application and should repair itself overthe course of two weeks by 75 percent. Constipation will reverse within12 hours.

Formulation 8

FIG. 7 depict Formulation 8. Within 24 hours of daily and nightlyapplication of the cream to elderly individuals. Formulation 8 will helpindividuals fall asleep within 30 minutes and will help individuals stayasleep throughout the night. The moisture should be 30 percent betterwithin first 24 hours of using the topical cream which goes into theblood stream similar to the patch. Wrinkles will subside by 15 percentwithin the first 48 hours of use.

Formulation 9

FIG. 8 depicts Formulation 9. Formulation 9 as a liposomal cream worksfor the elderly and youth who injure themselves. Once the application ofthe cream is applied, reduction of pain by 35 percent will occur within2 hours of use. Inflammation will subside by 50 percent in 24 hour use.Formulation 9 enters the blood stream on application and will acceleratethe healing process by clearing up the bruising within 48 hours.

Formulation 10

FIG. 9 depicts Formulation 10. Formulation 10 is for both men and womenwho struggle with insomnia. Once the transdermal patch is applied,people will fall asleep more easily within 20 minutes of application andwill sleep continuously sleep for a consecutive five hours withoutinterruption.

Formulation 11

FIG. 10 depicts Formulation 11. Once the transdermal patch is applied,Formulation 11 reduces the effects from alcohol by 25 percent within 12hours of intake. Also, Formulation 11 increases energy and focus thefollowing day. Reduction of puffiness in the face from stimulants isreduced by 30 percent the following day and abdominal inflammation isreduced by 20 percent the following day after consuming stimulants.

Formulation 12

FIG. 11 depicts Formulation 12. Formulation 12 aids in the reduction ofchronic headaches by 40 percent after applying a transdermal patch orgel. Reduction of migraine pain is reduced within one hour by 25 percentand headache pain by 70 percent within one hour of application. Itreduces recurring migraine pain from four hours to two hours then to 20minutes.

Formulation 13

FIG. 12 depicts Formulation 13. Formulation 13 can help with those withneurological issues such as Parkinson's. Many studies have shown thatthose with neurological issues have virtually no glutathione and greatlylack Vitamin D in the body. Mary is 62 and weighs 125 pounds before theapplication of the transdermal patch, her gait was heavily staggered,after wearing the patch, her gait reversed and it allowed her to walkcomfortably without a walker within the time span of 30 minutes. Jackwho is 74 with Parkinson's, weight 180 pounds, after wearing the patchhis gait reversed by 50 percent within one hour. Although he stillneeded a walker, he walked more comfortably.

Formulation 14

FIG. 13 depicts Formulation 14.

Phase A: In a suitable tank or vessel, add 54.55 weight percent ofpurified water. Start heating to 80° C. Into a separate suitablecontainer, disperse xanthan gum in glycerine. Then, add it into waterwhile mixing at medium speed. Continue heating to 80° C.

Phase B: Into another mixing vessel, mix 3 weight percent of isopropylemyristate, 6 weight percent cetearyl oliviate, 3 weight percentcaprylic/capric triglycerides, 3.5 weight percent stearyl alcohol, 3weight percent cetyl alcohol, 2 weight percent Helianthus annuus(sunflower) seed oil, and 5 weight percent soy lecithin of Phase B inorder. After all ingredients are added, turn the propeller on at low tomedium speed. Continue mixing and heating to 75-80° C.

Once the temperatures of phases A B are attained, using transfer pump,add phase B (Oil phase) into phase A (water phase) while mixingcontinuously at 2000-2500 rpm with the mixer. Mix for 5 minutes.

Start cooling the batch to 50° C., Then turn the propeller to LOW speedand keep the scraper at LOW speed, Turn on chiller while continue mixinguntil the temperature drops to 50° C.

Phase C: Prepare premix of 6 weight percent of purified water and 5weight percent of glutathione. At 50° C., add phase C premix into thebatch, part by part, while mixing at 2500-3000 rpm speed. Mix for 10minutes.

Phase D: At 50° C., add 0.5 weight percent essential oil into the batchslowly while mixing at medium speed. Mix for 10 minutes.

Phase E: Prepare premix of 3 weight percent water and 1.5 weight percentgeogard ultra and add it into the hatch at 50° C. Then, add 0.3 weightpercent glyceryl caprylate into the batch while mixing at 2500-3000 rpmspeed. Mix for 10 minutes.

Start cooling the batch to room temperature while mixing continuously at2500-3000 rpm speed. When temperature drops to 40° C., turn off themixer and continue cooling the batch to room temperature while mixingwith low speed scraper. Check and record initial pH. The pH should rangefrom 3.5-4.5.

Formulation 14 as a liposomal cream works for individuals who areexperiencing scrofulous eczema on the face. Once the application of thecream is applied, there is a reduction of oozing and itching by 25percent within the first hour of application. The desquamation of theskin subsides by 40 percent of the use for 76 hours, offering theindividual a reduced state of burning and discharged crust formationoften as a result from the itching. The eczema subsides overall by 50percent within the first 7 days of application.

Formulation 15

FIG. 14 depicts Formulation 15.

Phase A: In a suitable tank or vessel, add 49.550 weight percent ofpurified water. Start heating to 80° C. Into a separate suitablecontainer, disperse 0.65 weight percent xanthan gum in 3 weight percentglycerine. Then, add it into water while mixing at medium speed.Continue heating to 80° C.

Phase B: Into another mixing vessel, mix 3 weight percent of isopropylemyristate blended, 6 weight percent cetearyl oliviate, 3.5 weightpercent caprylic/capric triglycerides, 3.5 weight percent stearylalcohol, 3 weight percent cetyl alcohol, 5 weight percent of arnicamontana oil, 2 weight percent helianthus annuus seed oil, and 5 weightpercent soy lecithin in order. After all ingredients are added, turnpropeller on at low to medium speed. Continue mixing and heating to75-80° C.

Once the temperatures of phases A & B are attained, using transfer pump,add phase B (Oil phase) into phase A (water phase) while mixingcontinuously at 2000-2500 rpm with the mixer. Mix for 5 minutes.

Start cooling the batch to 50° C. Then turn the propeller to LOW speedand keep the scraper at LOW speed. Turn on chiller while continuouslymixing until the temperature drops to 50° C.

Phase C: Prepare premix of 6 weight percent of purified water and 5weight percent of glutathione. At 50° C., add phase C premix into thehatch slowly, part by part while mixing at medium speed. Mix for 10minutes.

Phase D: At 50° C., add 0.5 weight percent essential oil into the hatch,part by part, while mixing at 2500-3000 rpm speed. Mix for 10 minutes.

Phase E: Prepare premix of 3 weight percent water and 1.5 weight percentgeogard ultra and add it into the batch at 50° C. Then, add 0.3 weightpercent glyceryl caprylate into the batch while mixing at 2500-3000 rpmspeed. Mix for 10 minutes.

Start cooling the batch to room temperature while mixing continuously at2500-3000 rpm speed.

When temperature drops to 40° C., turn off the mixer and continuecooling the batch to room temperature while mixing with low speedscraper. Check and record initial pH. The pH can range from 3.5-4.5.

Formulation 15 as a liposomal cream works for post-surgical scarring.Once the application of the cream is applied, the redness and permeatedpresentation reduces by 15 percent within the first 24 hours. Over thecourse of applied cream for one month, the scaring on the affected partreduces by 80 percent allowing the individual to have a returned stateof healthier skin presentation.

Formulation 16

FIG. 15 depicts Formulation 16.

Phase A: in a suitable tank or vessel, add 49.550 weight percent ofpurified water. Start heating to 80° C. Into a separate suitablecontainer, disperse 0.6 weight percent xanthan gum in 3 weight percentglycerine. Then, add it into water while mixing at medium speed,Continue heating to 80° C.

Phase B: Into another mixing vessel, mix 3.5 weight percent ofisopropyle myristate, 6 weight percent cetearyl oliviate, 3.5 weightpercent caprylic, 3 weight percent stearyl alcohol, 3.5 weight percentcetyl alcohol, 2 weight percent of arnica montana oil, 2.05 weightpercent helianthus annuus seed oil, and 5 weight percent soy lecithin inorder. After all ingredients are added, turn propeller on at low tomedium speed. Continue mixing and heating to 75-80° C.

Once the temperatures of phases A & B are attained, using transfer pump,add phase B phase) into phase A (water phase) while mixing continuouslyat 2000-2500 rpm with the mixer. Mix for 5 minutes.

Start cooling the batch to 50° C. Then turn the propeller to LOW speedand keep the scraper at LOW speed. Turn on chiller while continue mixinguntil the temperature drops to 50″C.

Phase C: Prepare premix of 6 weight percent of purified water and 7weight percent glutathione. At 50° C., add phase C premix into the batchslowly, part by part while mixing at medium speed. Mix for 10 minutes.

Phase D: At 50° C., add 0.5 weight percent essential oil into the batch,part by part, while mixing at 2500-3000 rpm speed. Mix for 10 minutes.

Phase E: Prepare premix of 3 weight percent water and 1.5 weight percentgeogard ultra and add it into the batch at 50° C. Then, add 0.3 weightpercent glyceryl caprylate into the batch while mixing at 2500-3000 rpmspeed. Mix for 10 minutes.

Start cooling the batch to room temperature while mixing continuously at2500-3000 rpm speed.

When temperature drops to 40° C., turn off the mixer and continuecooling the batch to room temperature while mixing with low speedscraper. Check & record initial pH. The pH can range from 3.5-4.5.

Formulation 16 as a liposomal cream works for the elderly who areexperiencing insomnia. Once the application of the cream is applied, anhour before bed, the ability to fall asleep will increase 35 percentwill occur within 2 hours of use. The ability to sleep through the nightwill increase by 50 percent in first night of an eight hour sleep. Thisformula enters the blood stream on application.

Formulation 17

FIG. 16 depicts Formulation 17.

Phase A: in a suitable tank or vessel, add 52.550 weight percent ofpurified water. Start heating to 80° C. Into a separate suitablecontainer, disperse 0.65 weight percent xanthan gum in 3 weight percentglycerine. Then, add it into water while mixing at medium speed.Continue heating to 80° C.

Phase B: Into another mixing vessel, mix has 3 weight percent ofisopropyle myristate, 6 weight percent cetearyl oliviate, 3 weightpercent caprylic/capric triglycerides, 3.5 weight percent stearylalcohol, 3.2 weight percent cetyl alcohol, 3.80 weight percenthelianthus annuus seed oil, and 4 weight percent soy lecithin of Phase Bin order. After all ingredients are added, turn the propeller on at lowto medium speed. Continue mixing and heating to 75-80° C.

Once the temperatures of phases A & B are attained, using transfer pump,add phase B (Oil phase) into phase A (water phase) while mixingcontinuously at 2000-2500 rpm with the mixer. Mix for 5 minutes.

Start cooling the batch to 50° C. Then turn the propeller to LOW speedand keep the scraper at LOW speed. Turn on chiller while continue mixinguntil the temperature drops to 50° C.

Phase C: Prepare premix of 6 weight percent of purified water and 6weight percent of glutathione. At 50° C. add phase C premix into thebatch, part by part, while mixing at 2500-3000 rpm speed. Mix for 10minutes.

Phase D: At 50° C., add 0.5 weight percent essential oil into the batchslowly while mixing at medium speed. Mix for 10 minutes.

Phase B: Prepare premix of 3 weight percent water and 1.5 weight percentgeogard ultra and add it into the batch at 50° C. Then, add 0.3 weightpercent glyceryl caprylate into the batch while mixing at 2500-3000 rpmspeed. Mix for 10 minutes.

Start cooling the batch to room temperature while mixing continuously at2500-3000 rpm speed. When temperature drops to 40° C., turn off themixer and continue cooling the batch to room temperature while mixingwith low speed scraper. Check and record initial pH. The pH should rangefrom 15-4.5.

Formula 17 as a liposomal cream works for teenagers who are experiencingsevere acne. Once the application of the cream is applied on the face, areduction of cystic pimples starts to decrease by 35 percent within thefirst 48 hours of use while the reduction of white heads start to reduceby 45 percent. Over the course of two weeks, there is a reduction ofacne by 75 percent of the total face of the teenager and there is areduction of recurring cystic pimples.

While these embodiments have been described with emphasis on theembodiments, it should be understood that within the scope of theappended claims, the embodiments might be practiced other than asspecifically described herein.

What is claimed is:
 1. A transdermal formulation comprising: a. 4 weightpercent to 10 weight percent glutathione; b. 0.5 weight percent to 1weight percent Vitamin D; c. 18 weight percent to 20 weight percentglycol; d. 3 weight percent to 9 weight percent sodium bicarbonate; ande. 47 weight percent to 58 weight percent base cream, wherein the basecream is resilient in the presence of a wide range of drugs whileincreasing permeation of active antioxidant agents.
 2. The transdermalformulation of claim 1, comprising a carrier of a cream, a gel, or afoam.
 3. The transdermal formulation of claim 1, further applied to alatex-free hypoallergenic adhesive patch comprising: a. a formulationside and a back side, wherein a therapeutically effective amount of thetransdermal formulation is disposed on the formulation side of thelatex-free hypoallergenic adhesive patch; and b. a strip of magnesiumglycinate attached to the transdermal formulation, wherein a dosageamount of the transdermal formulation is placed on the latex-freehypoallergenic adhesive patch for delivery to a patient over a unit oftime for at least 24 hours to 48 hours; and wherein the dosage amountcreates in the patient (i) regulation of sleep; (ii) increased energyduring awake periods, (iii) improved concentration during awake periods,(iv) reduction of facial wrinkles, and (v) reduction of joint andmuscular pain with increases by at least 10 percent of the ability ofskin to retain moisture and totally absorb the glutathione withoutrequiring an injection or an oral supplementation of the glutathione. 4.The transdermal formulation of claim 1, wherein the glycol is apropylene glycol.
 5. The transdermal formulation of claim 4, whereinpropylene glycol is at least one of: polyethylene glycol distearate,polyethylene glycol monoalkylate, polyethylene glycol monostearate, andpolethyelene glycol monolaurate.
 6. The transdermal formulation of claim1, wherein the glycol is at least one of: glycerin, glycerolmonocapryate, glycerol monooleate, glycerol monostearate, glycerol tri2-ethylhexanoate.
 7. The transdermal formulation of claim 2, wherein thecarrier of the cream has a dosage amount which creates in the patient(i) regulation of sleep, (ii) increased energy during awake periods,(iii) improved concentration during awake periods, (iv) reduction offacial wrinkles, and (v) reduction of joint and muscular pain withincreases by at least 10 percent of the ability of skin to retainmoisture and totally absorb the glutathione without requiring aninjection or oral supplementation of the glutathione.
 8. The transdermalformulation of claim 1, comprising: 1 weight percent polyoxyethylenesorbitan monooleate.
 9. The transdermal formulation of claim 3, whereinthe latex-free hypoallergenic adhesive patch is waterproof.
 10. Thetransdermal formulation of claim 3, wherein the strip of magnesiumglycinate is a continuous strip extending from one side of thetransdermal formulation to the other side of the transdermalformulation.
 11. The transdermal formulation of claim 3, wherein thestrip of magnesium glycinate is a series of strips, which are offsetfrom each other.
 12. The transdermal formulation of claim 1, furthercomprising weight percent to 5 weight percent arnica.
 13. A transdermalformulation comprising: a. 4 weight percent to 10 weight percentglutathione; b. 75 weight percent to 85 weight percent water; c. 3weight percent to 4 weight percent sodium bicarbonate; and d. 0.1 weightpercent to 1 weight percent propylene glycol.
 14. The transdermalformulation of claim 13, comprising a carrier of a cream, a gel, or afoam.
 15. The transdermal formulation of claim 13, further applied to alatex-free hypoallergenic adhesive patch comprising: a. a formulationside and a back side, wherein a therapeutically effective amount of thetransdermal formulation is disposed on the formulation side of thelatex-free hypoallergenic adhesive patch; and b. a strip of magnesiumglycinate is attached to the transdermal formulation, wherein a dosageamount of the transdermal formulation is placed on the latex-freehypoallergenic adhesive patch for delivery to a patient over a unit oftime for at least 24 hours to 48 hours; and wherein the dosage amountcreates in the patient (i) regulation of sleep, (ii) increased energyduring awake periods, (iii) improved concentration during awake periods,(iv) reduction of facial wrinkles, and (v) reduction of joint andmuscular pain with increases by at least 10 percent of the ability ofskin to retain moisture and totally absorb the glutathione withoutrequiring an injection or an oral supplementation of the glutathione.16. The transdermal formulation of claim 15, wherein the latex-freehypoallergenic adhesive patch is waterproof.
 17. The transdermalformulation of claim 15, wherein the strip of magnesium glycinate is acontinuous strip extending from one side of the transdermal formulationto the other side of the transdermal formulation.
 18. The transdermalformulation of claim 15, wherein the strip of magnesium glycinate is aseries of strips which are offset from each other.
 19. The transdermalformulation of claim 13, further comprising 1 weight percent to 5percent arnica.
 20. A transdermal formulation comprising: a. 4 weightpercent to 10 weight percent glutathione; b. 47 weight percent to 56weight percent water; c. weight percent to 9 weight percent sodiumbicarbonate; d. 1 weight percent to 5 weight percent polyoxyethylenesorbitan monooleate; e. 2 weight percent to 5 weight percent ascorbicacid; and f. 4 weight percent to 10 weight percent dimethyl sulfoxide.21. The transdermal formulation of claim 20, wherein a carrier is atleast one of: a cream, a gel, or a foam.
 22. The transdermal formulationof claim 20, further applied to a latex-free hypoallergenic adhesivepatch, comprising: a. a formulation side and a back side, wherein atherapeutically effective amount of the transdermal formulation isdisposed on the formulation side of the latex-free hypoallergenicadhesive patch; and b. a strip of magnesium glycinate attached to thetransdermal formulation, wherein a dosage amount of the transdermalformulation is placed on the latex-free hypoallergenic adhesive patchfor delivery to a patient over a unit of time for at least 24 hours to48 hours; and wherein the dosage amount creates in the patient (i)regulation of sleep, (ii) increased energy during awake periods, (iii)improved concentration during awake periods, (iv) reduction of facialwrinkles, and (v) reduction of joint and muscular pain with increases byat least 10 percent of the ability of skin to retain moisture andtotally absorb the glutathione without requiring an injection or an oralsupplementation of the glutathione.
 23. The transdermal formulation ofclaim 22, wherein the latex-free hypoallergenic adhesive patch iswaterproof.
 24. The transdermal formulation of claim 22, wherein thestrip of magnesium glycinate is a continuous strip extending from oneside of the transdermal formulation to the other side of the transdermalformulation.
 25. The transdermal formulation of claim 22, wherein thestrip of magnesium glycinate is a series of strips which are offset fromeach other.
 26. The transdermal formulation of claim 22, furthercomprising 1 weight percent to 5 weight percent arnica.